Experts call for more clinical trials on alcohol use, liver disease

June 21, 2024
International task force issues recommendations to guide research into alcohol use disorder and to address stigma.

More clinical research is needed to investigate how reducing alcohol consumption in patients with alcohol-related liver disease (ALD) may slow disease progression and improve outcomes, according to an international task force of experts from more than two dozen institutions including UT Southwestern Medical Center. 

In a consensus statement published in Nature Reviews, the group, commissioned by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), issued a set of 28 recommendations to guide the design of future clinical trials addressing alcohol use disorder (AUD) and ALD. The recommendations call for multidisciplinary teams, including experts from hepatology and addiction medicine, and the need to address the stigma of alcoholism.

The task force included hepatologists, addiction medicine specialists, clinical trialists, and members of regulatory agencies. Among its recommendations are definitions for disease categories, criteria for trial participants, treatment considerations, and safety and regulatory concerns.

The article notes that diseases related to alcohol use are among the most stigmatized, resulting in stereotypes that create barriers to treatment, such as ineligibility for liver transplantation. The group proposed that researchers discuss ways to reduce those negative beliefs among all team members in trials for AUD and ALD and, when possible, involve patient representatives and other stakeholders in trial design.

UT Southwesten release on Newswise

By Pixel-Shot on Adobe Stock
adobestock_224306882
ID 7392706 © Dariusz Majgier | Dreamstime.com
dreamstime_xxl_7392706
ID 310202522 © Oleksandra Tsvid | Dreamstime.com
dreamstime_xxl_310202522_2
ID 292063206 © Artem Evdokimov | Dreamstime.com
dreamstime_xxl_292063206
ID 186157453 © Noipornpan | Dreamstime.com
dreamstime_xxl_186157453